SurModics (SRDX) Tops Q4 EPS by 11c; Approves Additional $20M Stock Buyback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
SurModics Reports Fourth Quarter Fiscal 2015 Results
November 10, 2015 7:35 AM ESTGAAP Revenue Growth of 13% to $17.4 Million and GAAP EPS of $0.22 Non-GAAP Revenue Up 8% and Non-GAAP EPS of $0.30 FDA IDE Approval for Early Feasibility Study of the SurVeil Drug-Coated Balloon Increase in Share Repurchase Authorization to $30.0 Million Fiscal 2016 Guidance Outlined
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2015 fourth... More
